US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based antibody-dependent cellular cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-

To access the full article, please log in or subscribe.